Non Small Cell Lung Cancer: Page 3

Thermo Fisher, Guardant Health get approval for NSCLC CDx

Enhertu is an HER2-directed antibody drug conjugate being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

August 11, 2022

Foundation Medicine highlights lung cancer study results

The findings are from the Prospective Clinicogenomic (PCG) study and were published August 5 in the Journal of Thoracic Oncology Clinical and Research Reports.

August 7, 2022

Biodesix touts VeriStrat test results

The blood-based test was predictive of progression-free survival and overall survival in patients with non-small cell lung cancer with low or negative PD-L1 treated with immune checkpoint inhibitors, the firm said.

July 19, 2022

BillionToOne launches liquid biopsy products for research

The products are available for research use in select academic cancer centers.

July 7, 2022

Biocartis, AstraZeneca to develop CDx for EGFR TKI treatment

The firms aim to obtain applicable premarket notification or approval from the U.S. Food and Drug Administration (FDA) for a CDx test on Biocartis' fully automated molecular Idylla platform.

June 21, 2022

Foundation Medicine gets FDA nod for NSCLC CDx

Rozlytrek is a targeted therapy for the treatment of non-small cell lung cancer (NSCLC) developed by Roche's Genentech.

June 8, 2022

Stilla and Promega sign comarketing agreement

The companies have combined Promega's Maxwell liquid biopsy system and Stilla's naica system, a six-color multiplexing digital PCR platform. The pairing enables an optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research, and drug discovery, according to the vendors.

April 7, 2022

Guardant wins new clearances in Japan for liquid biopsy test

The MHLW has cleared Guardant360 CDx for mutation profiling in patients with advanced solid tumors. In addition, it approved Guardant360 CDx as a companion diagnostic for identifying patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab (Keytruda). What's more, Guardant360 CDx has also been approved for patients with MSI-High advanced colorectal cancer who may benefit from nivolumab (Opdivo).

March 14, 2022

Insightec to launch new trials of Exablate Neuro

One study will evaluate the use of Exablate Neuro to treat patients with primary non-small cell lung cancer that has metastasized to the brain in conjunction with Keytruda, a humanized antibody immunotherapy. Exablate Neuro could be used to open up the blood-brain barrier to make immunotherapy agents like Keytruda more effective.

March 9, 2022

Invitae launches 2 IVD cancer tests in Europe

Both tests offer comprehensive genomic profiling and companion diagnostic use for solid tumor neoplasms, including non-small cell lung cancer, in tissue biopsy and where tissue is a limiting factor.

February 15, 2022

PierianDx, Biodesix partner on lung cancer diagnostics

PierianDx will provide its interpretation technology platform for use with Biodesix's newly launched GeneStrat NGS genomic test, a blood-based tumor profiling test that detects mutations -- including EGFR, ALK, and KRAS -- in patients with non-small cell lung cancer (NSCLC).

January 18, 2022

Lucence offers expanded cfRNA version LiquidHallmark

Researchers have found that adding RNA sequencing to DNA sequencing for tissue testing yields an additional 14% of "clinically actionable alterations," Lucence said. An internal study conducted by the firm found that "out of 112 non-small cell lung cancer samples, 29 fusions were detected with a combined cfDNA and cfRNA approach in plasma, compared with 20 fusions from cfDNA alone."

January 9, 2022

Previous Page

Page 3 of 5

Next Page